COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues
Bill of Health
JANUARY 12, 2023
Moderna also licensed their mRNA technology from Cellscript LLC – University of Pennsylvania’s successor-in-interest to the 966 patent. By 2009, before Moderna’s patent application, scientists knew that the full-length spike protein is highly immunogenic and can be used to induce protection against certain viruses.
316 
Let's personalize your content